Compare Atlassian Corporation PLC (TEAM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Atlassian Corporation PLC trades at $177.5 (market cap $44.99B), while State Street SPDR S&P Biotech ETF trades at $159.85. Which is the better fit depends on your goals.
| TEAM | XBI | |
|---|---|---|
Market Cap | $44.99B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $194.68 | $169.55 |
52-Week Low | $57.15 | $93.43 |
Enterprise Value | $44.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $176.42, down 6.94% over 24 hours but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and a neutral RSI. Fundamentally, revenue growth is robust, climbing to $5.22B in 2025, though net income margins are negative. Recent earnings beats and AI integration into products like Rovo highlight operational strength, but high valuations and insider sales warrant caution.
Outlook is cautiously optimistic; analyst consensus is bullish with a $179.81 price target, driven by AI adoption and cloud expansion. Risks include premium valuation metrics, persistent net losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
